Molecular approaches to cancer therapy
Most cancers are associated with mutations in the signalling proteins found in cells. A better understanding of the signalling pathways underlying many cancers is aiding progress in the development of novel molecular-targeted drug therapies.
The Maurice Wilkins Centre supports a range of projects that are focused on targeting signalling networks in cancer cells, or normal cells within the tumour microenvironment, and developing small molecule drugs for cancer therapy.
Our expertise in structure-based drug design is enabling us to develop drugs that target signalling molecules, in particular lipid kinases and tyrosine kinases.